Additionally, GLP-1 medications may slow down the rate at which the stomach empties after eating, increasing feelings of fullness and satisfaction
Around 50% of patients on higher doses lost 20% or more of their body weight
References include the SURMOUNT-1 trial publication (Jastreboff et al., New England Journal of Medicine, 2022), the Mounjaro and Zepbound prescribing information (Eli Lilly, 2024), Liu et al., JAMA Internal Medicine, 2018 (steroid-induced hyperglycemia), and American Diabetes Association Standards of Care, 2024
The oral segment is projected to hold a notable share of the market during the forecast period
Procedures like gastric sleeve and gastric bypass change how the stomach and intestines function
The reimbursement policy impact is substantial, with stringent prior authorization requirements and step-therapy protocols limiting access